The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | A single-cell analysis of MYD88-mutated and MYD88 wild-type Waldenström’s macroglobulinemia
Tina Bagratuni, PhD, National and Kapodistrian University of Athens, Athens, Greece, outlines the findings of a single-cell analysis of samples from patients with Waldenström’s macroglobulinemia (WM), which focused on examining the transcriptomic differences between MYD88-mutated and wild-type WM. Although they only represent around 5% of cases, the MYD88 wild-type patients exhibit distinct and aggressive disease profiles, lacking memory B-cell characteristics commonly seen in mutated cases. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
